Design Therapeutics Inc

General ticker "DSGN" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $348.5M

Design Therapeutics Inc follows the US Stock Market performance with the rate: 56.1%.

Estimated limits based on current volatility of 3.7%: low 5.88$, high 6.34$

Factors to consider:

  • Current price 27.8% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.80$, 4.97$]
  • 2024-12-30 to 2025-12-30 estimated range: [2.08$, 5.28$]

Financial Metrics affecting the DSGN estimates:

  • Negative: Non-GAAP EPS, $ of -1.20 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -29.77 <= 2.35
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term DSGN quotes

Long-term DSGN plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $35.83MM $67.59MM $78.19MM
Operating Income $-35.83MM $-67.59MM $-78.19MM
Non-Operating Income $0.30MM $4.29MM $11.33MM
R&D Expense $24.78MM $48.61MM $57.06MM
Income(Loss) $-35.53MM $-63.31MM $-66.86MM
Profit(Loss) $-35.53MM $-63.31MM $-66.86MM
Stockholders Equity $382.13MM $327.31MM $277.69MM
Inventory $1.25MM $1.11MM $0.00MM
Assets $390.56MM $341.14MM $289.64MM
Operating Cash Flow $-29.38MM $-51.32MM $-58.56MM
Capital expenditure $1.54MM $0.92MM $0.26MM
Investing Cash Flow $-53.64MM $-220.99MM $52.54MM
Financing Cash Flow $379.21MM $0.23MM $0.72MM
Earnings Per Share* $-0.77 $-1.05 $-1.19

* EPS are Split Adjusted, recent splits may be reflected with a delay.